Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria
Andreas Seeber1, Lukas Weiss2, Franz Romeder3
1Department of Internal Medicine V: Hematology and Oncology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. andreas.seeber@tirol-kliniken.at.
Background:
Olaratumab is a humanized monoclonal antiplatelet-derived growth factor receptor alpha antibody that has been approved in combination with doxorubicin for the treatment of patients with metastatic soft tissue sarcoma (STS). The purpose of this retrospective study was to assess the clinical efficacy in STS patients treated with olaratumab in a real-world setting in Austria.
Methods:
Retrospectively collected longitudinal data from patients treated between November 2016 and September 2018 at 9 Austrian centers were obtained from the respective medical charts. All patients who received at least one dose of olaratumab were eligible. Parameters of most interest were response rates, progression-free survival (PFS) and overall survival (OS).
Results:
Altogether 55 patients were included in the analysis. The median age was 58 years. In total, 65.5% (n = 36), 21.8% (n = 12) and 12.7% (n = 7) received olaratumab as first, second or ≥third line treatment, respectively. Olaratumab was administered either in combination with doxorubicin (81.8%, n = 45) or liposomal doxorubicin (16.4%, n = 9); one patient received olaratumab as upfront monotherapy. The median PFS and OS were 2.6 and 11.4 months, respectively. The objective response rate was 11.4% and the disease control rate was 40.9%.
Conclusion:
In this real-world analysis the outcome was less pronounced compared to the results of both the phase Ib/II approval trial and the confirmatory phase III trial. The latter failed to show an improvement in OS and PFS for the doxorubicin/olaratumab combination. As such, olaratumab should not be used anymore in patients with STS.
Insights
Real-world data shows olaratumab combined with doxorubicin had less pronounced efficacy in metastatic soft tissue sarcoma (STS) patients. This study suggests discontinuing olaratumab for STS treatment due to suboptimal outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Olaratumab, a monoclonal antibody targeting platelet-derived growth factor receptor alpha, is approved for metastatic soft tissue sarcoma (STS) in combination with doxorubicin.
- Real-world treatment efficacy of olaratumab in STS patients in Austria was previously unevaluated.
Purpose of the Study:
- To assess the clinical efficacy of olaratumab in a real-world Austrian setting for patients with metastatic soft tissue sarcoma (STS).
Main Methods:
- Retrospective analysis of longitudinal data from 55 STS patients treated across 9 Austrian centers between November 2016 and September 2018.
- Data collected from medical charts included response rates, progression-free survival (PFS), and overall survival (OS).
Main Results:
- The median progression-free survival (PFS) was 2.6 months, and median overall survival (OS) was 11.4 months.
- Objective response rate was 11.4%, and disease control rate was 40.9%.
- Most patients (81.8%) received olaratumab with doxorubicin, with 65.5% receiving it as first-line treatment.
Conclusions:
- Real-world outcomes for olaratumab in STS were less favorable than reported in clinical trials.
- The confirmatory phase III trial did not demonstrate improved OS or PFS for the doxorubicin/olaratumab combination.
- Based on these findings, olaratumab is not recommended for future use in STS patients.
